When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

Key Takeaways

• Capital discipline is changing R&D strategy, not just funding levels, forcing biopharma companies to redesign portfolios around measurable returns, milestone economics, and capital efficiency rather than broad exploratory breadth.

• Fewer shots on goal reduce scientific optionality, making backup programs, long-cycle research, and exploratory platforms harder to sustain as portfolios narrow and early kill criteria become more aggressive.

• Platform strategies are becoming more constrained and mechanistically focused, as productivity pressures and cycle-time management favor science that can be validated, scaled, and financed within tighter timelines.

• Manufacturability and translation are moving upstream in drug development, with capital increasingly favoring programs that integrate execution, scalability, and clinical feasibility earlier in the R&D lifecycle.

• Capital discipline now acts as a scientific selection mechanism, determining not only which companies succeed, but which mechanisms, modalities, and development pathways are prioritized across the biopharma ecosystem.

Capital discipline in biopharma is often described as a simple contraction of available funding, but that framing largely misses the paradigm shift that is now underway. What is changing is not just how much capital is available but how rigorously that capital is interrogated, allocated, and defended. In an environment where returns are tracked closely and performance is benchmarked publicly, portfolio design becomes a strategic variable itself rather than merely a background assumption. Decisions about which programs advance, which remain optional, and which are abandoned earlier are increasingly shaped by explicit expectations around value creation, not just scientific promise.

This shift reflects a broader redefinition of what “productive” R&D means. Industry analyses now frame R&D productivity in economic terms, linking outcomes to revenue generated per dollar invested and forcing organizations to think in portfolio-level tradeoffs rather than individual program narratives.¹ At the same time, headline metrics such as forecast internal rate of return (IRR) have re-entered boardroom conversations, reinforcing the idea that capital efficiency and scientific ambition are no longer separable considerations. Under these conditions, capital discipline functions less as a blunt constraint and more as a selection mechanism, shaping which types of science are structurally favored.

This recalibration is occurring against the backdrop of ongoing productivity and timing pressures within the development engine itself. Industry-wide analyses show that companies are actively managing cycle-time components and development efficiency, with particular attention to late-stage success rates and the intervals between trials.² Improvements in some areas currently coexist with ongoing constraints in others, which underscores why portfolio decisions are increasingly made with an eye toward the pacing of milestones and cumulative capital exposure rather than long-horizon optionality (i.e., degree of strategic and scientific flexibility a company preserves within its R&D portfolio) alone. Together, these forces set the stage for a deeper examination of how fewer “shots on goal” reshape not just financial outcomes, but the underlying scientific strategies that biopharma organizations are willing (or able) to pursue.

The narrowing of R&D portfolios is often framed as a temporary response to tighter funding conditions, but evidence suggests it represents a deeper structural shift with lasting scientific consequences. As definitions of R&D productivity evolve, portfolios are increasingly evaluated through an explicitly economic lens, emphasizing returns generated per dollar invested rather than the cumulative breadth of exploratory effort. This reframing turns portfolio construction into an optimization problem, where the question is not simply whether individual programs are scientifically compelling but whether the overall mix of programs can justify continued capital deployment under increasingly explicit performance benchmarks.

Within this framework, the concept of “shots on goal” takes on renewed importance. Portfolio analyses emphasize that outlier outcomes (e.g., the assets that ultimately deliver disproportionate value) rarely emerge from narrowly concentrated pipelines. Maintaining a sufficient number of parallel scientific bets is seen as essential to preserving the probability of such breakthroughs, even as capital discipline demands tighter governance and clearer kill criteria (predefined, evidence-based thresholds that determine when an R&D program should be paused or terminated).¹ The tension is inherent: capital efficiency drives activities toward a focus, while value creation at scale still depends on a degree of portfolio breadth.

For early-stage companies in particular, this tension is sharpened by venture capital (VC) dynamics. Research examining VC-backed biotechs shows that specialized investors often steer companies toward a smaller number of lead programs, accelerating prioritization decisions and compressing optionality earlier in the company life cycle. While this focus can improve clarity and capital efficiency, it also reduces the buffer that alternative programs traditionally provide when lead candidates falter.³ As a result, portfolio compression under capital discipline does not merely change how portfolios are managed; they alter the risk profile of the science itself, increasing the stakes attached to each remaining program and reshaping the kinds of research questions that organizations are willing to pursue.

Capital discipline becomes most visible not in high-level strategy statements but in the day-to-day mechanics of R&D decision-making. As financial scrutiny intensifies, portfolio governance processes increasingly determine which programs are funded, which are paused, and which are terminated earlier than they might have been in a more permissive environment. Rather than serving as a backdrop to scientific planning, capital considerations now sit alongside biology and clinical rationale as explicit inputs into portfolio review.

Recent analyses of industry performance reinforce the idea that portfolio composition itself can materially influence outcomes. The recovery in forecast IRR among large biopharma companies has been framed not as a consequence of higher spending but as the result of more deliberate portfolio choices: shifts toward assets and programs with clearer value trajectories and more disciplined capital allocation across the pipeline.⁴ In this view, portfolio architecture becomes an active lever for improving returns, with decisions about concentration, sequencing, and program mix carrying financial consequences that are now tracked and debated explicitly.

This framing elevates portfolio design from an internal planning exercise to a core driver of corporate performance. Programs are increasingly evaluated not only on their individual merits but on how they contribute to an aggregate risk–return profile that can withstand external scrutiny. As a result, capital discipline manifests as sharper prioritization thresholds and a willingness to reallocate resources away from programs that dilute portfolio-level performance, even if those programs remain scientifically interesting in isolation.⁴

The same forces that reward focus and selectivity also introduce a less visible tradeoff. Evidence from VC-backed companies suggests that as portfolios narrow and attention concentrates on fewer lead programs, the capacity to sustain alternative lines of inquiry can diminish.³ This compression of optionality can accelerate decision-making and clarify narratives for investors, but it also reduces the resilience that broader portfolios historically provided when early hypotheses failed.

For early programs in particular, this dynamic reshapes risk in subtle ways. When fewer products advance in parallel, the failure of a lead asset carries greater strategic weight, increasing pressure on remaining programs to succeed on tighter timelines. While this outcome follows logically from the push toward capital efficiency, it underscores how capital discipline can influence not just which programs move forward, but how much scientific uncertainty an organization is structurally prepared to absorb.

In operational terms, “optional programs” are best understood not as speculative science but as lines of exploration that are scientifically plausible and strategically interesting yet not strictly required to achieve the next value-defining milestone. They often sit adjacent to a lead program, extending a platform into new indications, mechanisms, or modalities or probing alternative biological hypotheses that may mature over longer timelines. Historically, these programs served as both intellectual insurance and strategic flexibility, allowing organizations to adapt when early assumptions proved incomplete or incorrect.

Under conditions of heightened capital discipline, however, optional programs become structurally fragile. As R&D productivity is increasingly framed as revenue generated per dollar invested, portfolios are evaluated through an optimization lens that prioritizes near-term contribution to value creation.¹ In this context, programs that cannot be clearly tied to the next inflection point, such as a clinical readout, partnership trigger, or financing event, are more difficult to defend, regardless of their longer-term scientific potential. The pressure to demonstrate capital efficiency compresses timelines and elevates the importance of immediacy, leaving less room for exploration that does not map cleanly onto short-term objectives.

This fragility is amplified by the concurrent emphasis on maintaining a broader sert of development bets. Advisory frameworks continue to stress that outlier successes overwhelmingly depend on the breadth of a portfolio, but capital discipline forces organizations to reconcile this principle with finite resources.¹ The result is a narrowing of what qualifies as an acceptable shot: programs that lack a clear path to value realization within the current planning horizon are often reclassified from optional to expendable, even if they would have been sustained under earlier funding regimes.

For venture-backed companies, the redefinition of optionality occurs even earlier. Evidence suggests that specialized investors tend to steer startups toward a smaller number of prioritized programs, accelerating focus but simultaneously cutting exploratory work that does not reinforce the core thesis behind the investment.³ In practice, this means optional programs are frequently pruned before they have a chance to generate validating data, reducing the organization’s ability to pivot scientifically if a lead asset underperforms. Taken together, these dynamics explain why optional programs are often the first casualties of capital discipline, not because they lack scientific merit but because their value is harder to quantify under increasingly constrained portfolio economics.

Concerns about platform strategies becoming narrower are often framed in abstract terms, but changes in R&D composition can be examined more concretely through observable shifts in modality mix and development dynamics. Industry-wide data suggest that the balance of scientific approaches advancing through the pipeline is evolving in ways that reflect both this intensified capital discipline and changing perceptions of overall risk. Rather than signaling a wholesale retreat from platform thinking, this likely indicates a more selective interpretation of what platforms are expected to deliver within defined economic and temporal constraints.

One indicator of this evolution is the declining share of small molecule programs across development phases. Analyses tracking global R&D activity show that small molecules account for a smaller proportion of phase I, II, and III starts today than they did a decade ago, pointing to a diversification of modalities and a reweighting of scientific bets.² While this trend does not imply uniform narrowing across all organizations, it suggests that platform strategies are increasingly anchored to specific mechanistic or technological domains rather than broad, modality-agnostic exploration. In practice, platforms are being asked to demonstrate clearer lines of sight to differentiated assets, often within narrower mechanistic boundaries.

At the same time, development timing considerations reinforce this focus. Key cycle-time elements, such as inter-trial intervals, have stabilized at lower levels after a peak earlier in the decade, which reflects concerted efforts to manage development efficiency and reduce idle time between studies.² As these intervals become more predictable, milestone economics are emerging as a dominant lens for big-picture planning. Programs and platforms that can align mechanistic exploration with disciplined milestone progression are easier to integrate into capital planning frameworks than those requiring prolonged periods of open-ended investigation.

Overlaying these trends is a renewed emphasis on specific productivity improvements, particularly in late-stage development. Better phase III success rates have been highlighted as a meaningful contributor to overall productivity, underscoring the value placed on de-risking mechanisms before they reach the most capital-intensive stages of development.² Taken together, these dynamics help explain why some platforms appear to be narrowing mechanistically. The change is less about abandoning platform ambition and more about constraining it within scientific and operational parameters that are compatible with tighter capital allocation and increasingly explicit expectations around development efficiency.

As milestone economics become the dominant framework for evaluating R&D progress, the types of science that struggle to survive are not necessarily those with weak biological rationale, but those whose value cannot be credibly demonstrated within compressed planning horizons. When productivity is defined in terms of revenue over investment, programs must show a plausible connection to near-term value creation to remain competitive for resources.1 Research paths that require extended periods of uncertainty before yielding decisive data become harder to justify, regardless of their potential importance over longer time scales.

This dynamic places particular pressure on longer-cycle bets and broadly exploratory work. Portfolio guidance continues to emphasize the need for a larger portfolio of parallel programs to preserve the probability of outlier successes, but capital discipline forces organizations to attempt to make this work with finite resources. As portfolios concentrate, tradeoffs become unavoidable. Optional programs, early mechanistic probes, and exploratory extensions of platforms are often the first to be paused or terminated, not because they fail scientific scrutiny but because they dilute the portfolio’s ability to deliver timely milestones under constrained capital conditions.

The same pressures are evident in the broader industry context. Commentary on the state of biopharma R&D highlights the sheer volume of candidates in development alongside rising costs, longer timelines, and the looming impact of patent expirations, all of which intensify scrutiny on how capital is deployed. In such an environment, science that cannot be staged into clearly articulated milestones or that competes poorly against nearer-term alternatives is increasingly marginalized. Milestone economics, in effect, act as a filter, shaping not only which programs advance but which scientific questions organizations are structurally willing to pursue.

Capital discipline is reshaping which science advances and questions of manufacturability and translation are expected to be resolved. A growing body of industry commentary argues that investors are no longer willing to treat manufacturing readiness as a downstream concern, to be addressed after biological risk has been retired. Instead, the ability to demonstrate credible paths to scalable production, quality control, and eventual patient access is increasingly treated as an early gating criterion for continued investment. This shift reflects the same logic that governs program selection more broadly: the earlier sources waste and value decline can be identified, the easier it becomes to justify the overall capital allocation.

From a portfolio-economics perspective, the logic is straightforward. When productivity is evaluated in conventional terms and portfolios are managed under explicit capital constraints, downstream failures tied to manufacturing complexity or scale-up challenges become disproportionately costly.¹ Addressing manufacturability earlier in development reduces the risk that substantial clinical investment will be stranded by problems that could have been anticipated and mitigated upstream. As a result, translational considerations increasingly influence which programs are advanced, paused, or deprioritized.

This view has been well articulated by industry leaders with direct experience spanning venture creation, large-scale manufacturing buildouts, and strategic transactions. Perspectives emerging from that vantage point emphasize that capital is becoming more discerning, with a growing preference for programs that integrate scientific ambition with practical execution plans. In this framing, manufacturing is no longer an operational afterthought but a core component of the value proposition, shaping investor confidence alongside biology and clinical data. Importantly, this does not imply that science is being subordinated to process but that scientific strategies are increasingly expected to demonstrate compatibility with real-world production constraints early enough to inform portfolio decisions.

The strategic value placed on early manufacturing capability is also reflected in recent consolidation activity within the biopharma services ecosystem. The acquisition of a controlling interest in the Center for Breakthrough Medicines (CBM) by a global manufacturing organization provides a concrete example of how scale, flexibility, and integrated development capabilities are being valued as strategic assets.⁵ While such transactions cannot be taken as proof of a single industry-wide doctrine, they do signal that the intersection of science and production is increasingly central to how value is defined and transacted.

Taken together, these developments underscore a broader shift in how capital discipline manifests across the development life cycle. As portfolios narrow and optionality decreases, the tolerance for late-stage surprises diminishes. Manufacturing and translation considerations therefore move upstream, not as constraints imposed on innovation but as filters that help determine which scientific programs are viable within a more exacting capital environment.

The cumulative effect of capital discipline is not confined to individual programs or companies; it is reshaping expectations and behaviors across the broader biopharma ecosystem. As portfolios narrow and scrutiny intensifies, different stakeholders encounter distinct but interrelated pressures that reflect the same underlying logic: capital must be deployed in ways that are both scientifically credible and economically defensible.

For R&D leaders, this environment demands more explicit portfolio governance. Managing portfolio-level risk diversification is no longer an abstract principle but a deliberate balancing act between preserving enough scientific breadth to enable outlier outcomes and maintaining near-term capital efficiency. When productivity is defined in economic terms, leaders must actively decide which programs justify continued optionality and which dilute the portfolio’s ability to deliver value within constrained planning horizons.¹ These decisions increasingly require transparent criteria and a willingness to make tradeoffs earlier than in prior funding cycles.

Emerging biotechs face a sharper version of this challenge. Evidence that venture-backed companies are being steered toward fewer prioritized programs underscores the importance of platform clarity and milestone design from the outset.³ With less tolerance for diffuse narratives, early-stage organizations must articulate how their science translates into a focused set of value-defining inflection points. The result is a higher premium on coherence and execution, but also a narrower margin for scientific course correction if early assumptions fail.

Productivity and timing dynamics remain a unifying concern. Ongoing efforts to manage cycle-time components and improve late-stage success rates signal that development efficiency will continue to anchor planning and evaluation processes.² As these metrics evolve, they will further influence how portfolios are constructed and how risk is distributed across programs. In aggregate, the ecosystem implications of capital discipline point toward a more interconnected model of innovation in which scientific ambition, operational readiness, and capital strategy are increasingly inseparable.

For contract development and manufacturing organizations (CDMOs), capital discipline in biopharma R&D is not a background condition; it is reshaping demand signals, partnership expectations, and the definition of value creation. As sponsors narrow pipelines, compress optionality, and anchor decisions to measurable milestones, the role CDMOs play across the asset life cycle is changing in both scope and timing.

One immediate implication is a shift in when CDMOs are engaged. As manufacturability and translation move upstream, sponsors increasingly expect development partners to contribute earlier in the scientific process rather than simply execute against late-stage specifications. Under portfolio economics that penalize late-stage failure and downstream value leakage, manufacturing feasibility, process robustness, and scale-up logic become part of the initial investment case rather than post hoc considerations.¹ This elevates CDMOs from capacity providers to risk-mitigating partners whose input can influence whether programs remain fundable within constrained portfolios.

Capital discipline also reshapes the mix of assets that reach CDMOs. Narrower pipelines and fewer parallel programs mean that individual assets carry more strategic weight for sponsors, increasing sensitivity to execution risk. Failed tech transfers, scale-up delays, or quality deviations now have amplified consequences when fewer opportunities remain. As a result, CDMOs are being evaluated not only on technical competence, but on their ability to reduce uncertainty across development milestones, align with sponsor timelines, and preserve capital efficiency through predictable execution.²

At the same time, the early narrowing of venture-backed pipelines changes the commercial dynamics of CDMO engagement. Emerging biotechs under pressure to focus on one or two lead programs often seek partners who can support rapid progression through defined milestones without requiring redundant development work. This favors CDMOs that can integrate development, analytics, and manufacturing under a coherent operating model, reducing handoffs and cycle-time friction.³ In this environment, modularity, flexibility, and data continuity become competitive differentiators.

Finally, capital discipline influences how CDMOs position themselves within the broader ecosystem. Sponsors and investors alike look for evidence that manufacturing partners can scale with the asset, adapt as programs evolve, and support eventual commercialization without forcing costly redesigns. For CDMOs, this means that strategic value is less about maximum throughput and more about enabling sponsors to survive — and succeed — in portfolios where there is little room for error.

In aggregate, the reworking of R&D portfolios under capital discipline pushes CDMOs closer to the center of biopharma strategy. As scientific optionality declines and milestone economics dominate, development and manufacturing partners become critical participants in determining which assets advance, how efficiently they progress, and whether capital invested in them can ultimately be defended.

What Counts as an “Optional Program” in 2026?

As capital discipline tightens, the definition of an “optional program” is becoming more explicit and more consequential. For R&D leaders, optionality is no longer an abstract hedge against uncertainty, but a category that must be actively governed. Based on how productivity, portfolio optimization, and venture dynamics are now framed, an optional program in 2026 is likely to share several characteristics.

• First, it is science that is credible but not required to reach the next value-defining milestone. If a program does not materially increase the probability of hitting a near-term clinical, regulatory, or partnering inflection point, it will struggle to justify continued capital allocation when productivity is measured as return per R&D dollar.

• Second, it is work whose value proposition cannot be clearly articulated within current runway constraints. Even when advisors emphasize the need for multiple shots on goal, optional programs are the ones most exposed when portfolio breadth competes directly with cash preservation and milestone pacing.

• Third, it is exploration that sits outside the core investment narrative. In venture-backed settings, programs that do not reinforce the primary platform thesis or lead asset story are often narrowed or deferred early, reducing the organization’s ability to pivot if initial hypotheses fail.

• Finally, optional programs are those that lack a clear line of sight to downstream execution. As manufacturability and translation move upstream in decision-making, exploratory efforts that do not yet engage with development feasibility or scale considerations are harder to protect in capital-constrained portfolios.

Taken together, optional programs in 2026 are less about scientific curiosity and more about strategic timing. They are not eliminated because they are uninteresting, but because they are misaligned with how value is now defined, sequenced, and defended under capital discipline.

What emerges from this landscape is a clearer understanding of capital discipline not merely as financial restraint but as a decisive scientific selection mechanism. As productivity is increasingly defined in explicitly economic terms, portfolio design itself becomes the primary arena in which scientific ambition is filtered, prioritized, and constrained.¹ Decisions about which programs advance are no longer driven solely by biological plausibility, but by how convincingly that biology can be translated into value within finite capital and time horizons.

This shift sharpens an enduring tension. Advisors and industry analyses continue to emphasize that meaningful innovation depends on maintaining a sufficientlky diversified portfolio to allow outlier successes to emerge.¹ However, the realities of runway management and investor expectations force organizations — especially venture-backed biotechs — to concentrate resources earlier, reducing optionality and raising the stakes attached to each remaining program.³ The result is a narrower funnel through which science must pass, increasing both the efficiency and fragility of R&D strategies.

At the ecosystem level, the implications extend beyond discovery and development. The movement of manufacturability and translation considerations upstream reflects a broader recalibration of what it means for science to be investable. Execution credibility now sits alongside biology as a prerequisite for sustained capital support.⁵ This does not diminish the importance of innovation, but it may redefine the conditions under which innovation can survive and scale.

Taken together, these dynamics suggest that capital discipline does more than tighten portfolios; it reshapes the contours of biopharma science itself. Capital discipline determines what gets explored, what gets protected through uncertainty, and what ultimately earns the resources required to reach patients. In that sense, today’s funding environment is not just selecting companies; it is selecting scientific strategies, mechanisms, and development pathways that fit within a more exacting, economically grounded model of innovation.

1. “Redefining Biopharma R&D Productivity: New Insights and Strategies.” L.E.K. Consulting. 2025.

2. Global Trends in R&D 2025. IQVIA. Mar. 2025.

3. Li, Xuelin, et al. “How Does Venture Capital Shape Biotech Innovation.” Promarket. 25 Apr. 2025.

4. Buntz, Brian. “From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb.” Drug Discovery and Development. 1 May 2025.

5. SK pharmteco to Expand Capabilities with Acquistion of Controlling Interest in Center for Breakthrough Medicines. Business Wire. 20 Sep. 2023.